NCT01636466 - The Everolimus-Transplant Exit Strategy Trial (E-TEST) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions

Kidney Failure, Chronic

Interventions

DRUG

Everolimus

Everolimus will initially be dosed at 0.75 mg tablet taken orally twice a day. The dose will be adjusted to maintain serum trough concentrations of 5-8 ng/ml.

Trial Locations (1)

30322

Emory University, Atlanta